TITLE

Intention-to-treat analysis: Protecting the integrity of randomization

AUTHOR(S)
Mahaniah, Kiame J.; Rao, Goutham
PUB. DATE
August 2004
SOURCE
Journal of Family Practice;Aug2004, Vol. 53 Issue 8, p644
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Randomization is a crucial part of most clinical trials. The purpose of randomization in a trial comparing 2 groups is to ensure that the groups differ only with respect to the interventions being compared. Randomization determines not only which treatment subjects receive, but also how the results are analyzed at the end of the trial. This article focuses on the protection of the integrity of randomization by intention-to-treat analysis. The intention-to-treat principle states that all subjects must be analyzed with respect to the group to which they were randomized.
ACCESSION #
14142083

 

Related Articles

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. Hanley, Bec; Truesdale, Ann; King, Andy; Elbourne, Diana; Chalmers, Iain // BMJ: British Medical Journal (International Edition);03/03/2001, Vol. 322 Issue 7285, p519 

    Conclusions: Consumer involvement in the design and conduct of controlled trials seems to be growing and seems to be welcomed by most researchers. Such involvement seems likely to improve the relevance to consumers of the questions addressed and the results obtained in controlled trials.

  • Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. Evans; Pocock; Lievre, Michel; Menard, Joel; Bruckert, Eric; Cogneau, Joel; Delahaye, Francois; Giral, Philippe; Leitersdorf, Eran; Luc, Gerald; Masana, Luis; Moulin, Philippe; Passa, Philippe; Pouchain, Denis; Siest, Gerard // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p603 

    Discusses premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. Reasons why some trials are discontinued prematurely by their sponsor for strategic reasons; How public financial and scientific participation in some trials and increasing the...

  • Monitoring and Ensuring Safety During Clinical Research. Morse, Michael A.; Califf, Robert M.; Sugarman, Jeremy // JAMA: Journal of the American Medical Association;3/7/2001, Vol. 285 Issue 9, p1201 

    Addresses concerns regarding the protection of human subjects in clinical trials. Description of the manner in which adverse event reporting might function to enhance safety; Role of data monitoring committees in using aggregate data from these reports; Problems that exist for institutional...

  • CONSORT statement: extension to cluster randomised trials. Campbell, Marion K.; Elbourne, Diana R.; Altman, Douglas G. // BMJ: British Medical Journal (International Edition);3/20/2004, Vol. 328 Issue 7441, p702 

    Offers a look at the effective reporting of randomized controlled trials. Guidelines in the Consolidated Standards of Reporting Trials (CONSORT) statement; Discussion of methodological issues in cluster randomized trials; Quality of reporting of cluster trials; Extension of CONSORT statement to...

  • A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Lene Thorsen; Kerry Courneya; Clare Stevinson; Sophie Fosså // Supportive Care in Cancer;Sep2008, Vol. 16 Issue 9, p987 

    Abstract Introduction  We reviewed physical activity (PA) studies in prostate cancer (PC) survivors investigating (a) the effects of PA on health outcomes, (b) the prevalence of PA, and (c) the determinants of PA. Materials and methods  A systematic search of the literature...

  • Communicating the Results of Clinical Research to Participants: Attitudes, Practices, and Future Directions. Shalowitz, David I.; Miller, Franklin G. // PLoS Medicine;May2008, Vol. 5 Issue 5, pe91 

    The authors discuss the available data on the effects of communicating aggregate and individual research results on participants, investigators, and the research enterprise.

  • Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Jain, Rakesh K. // Nature Reviews Cancer;Apr2008, Vol. 8 Issue 4, p309 

    The importance of multidisciplinary translational clinical trials is obvious; however, making them work is complex and challenging. Here I present an argument for designing and implementing multidisciplinary mechanistic trials and present the lessons our team at the Massachusetts General...

  • Rules for drug trials should be tightened, say experts. Kmietowicz, Zosia // BMJ: British Medical Journal (International Edition);8/5/2006, Vol. 332 Issue 7562, p276 

    The article offers a news brief about a report by the British government's Commission on Human Medicines that says that new high-risk drugs in phase I studies should be given to a single person at a time with observation time between doses. Phase I studies are the first time drugs are tested in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics